Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors-Reference-Cited by-同舟云学术

Population Pharmacokinetic Analysis of Pexidartinib in Healthy Subjects and Patients With Tenosynovial Giant Cell Tumor or Other Solid Tumors

Published:2020-10-11 Issue:4 Volume:61 Page:480-492
ISSN:0091-2700
Container-title:The Journal of Clinical Pharmacology
language:en
Short-container-title:The Journal of Clinical Pharmacology

Author:

Yin Ophelia¹,Wagner Andrew J.²,Kang Jia³,Knebel William³,Zahir Hamim¹,Sande Michiel⁴,Tap William D.⁵,Gelderblom Hans⁴,Healey John H.⁵,Shuster Dale⁶,Stacchiotti Silvia⁷

Affiliation:

1. Quantitative Clinical Pharmacology and Translational Sciences Daiichi Sankyo, Inc. Basking Ridge New Jersey USA

2. Dana‐Farber Cancer Institute Boston Massachusetts USA

3. Metrum Research Group Tariffville Connecticut USA

4. Leiden University Medical Center Leiden The Netherlands

5. Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College New York New York USA

6. Global Oncology R&D Daiichi Sankyo, Inc. Basking Ridge New Jersey USA

7. Fondazione IRCCS Istituto Nazionale dei Tumori Milan Italy

Funder

National Institutes of Health

National Cancer Institute

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jcph.1753

Reference16 articles.

1. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor

2. 2020 Daiichi Sankyo Inc Basking Ridge NJ

3. DK Vandell AG M Desai Effect of dose strength food and pH modifiers on the pharmacokinetics of the multi‐kinase inhibitor pexidartinib

4. Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

5. GastonguayMR.Full covariate models as an alternative to methods relying on statistical significance for inferences about covariate effects: a review of methodology and 42 case studies. PAGE Conference. June 2011. Athens Greece. Abstract 2229.www.page-meeting.org/?abstract=2229.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Physiologically Based Pharmacokinetic Absorption Model for Pexidartinib to Evaluate the Impact of Meal Contents and Intake Timing on Drug Exposure;Clinical Pharmacology in Drug Development;2024-02-23

2. CSF-1R in Cancer: More than a Myeloid Cell Receptor;Cancers;2024-01-09

3. Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model‐informed Drug Development Strategy;Clinical Pharmacology in Drug Development;2023-03-21

4. Pharmacokinetics of the Multi‐kinase Inhibitor Pexidartinib: Mass Balance and Dose Proportionality;Clinical Pharmacology in Drug Development;2022-11-11

5. Evaluation of Absorption and Metabolism-Based DDI Potential of Pexidartinib in Healthy Subjects;Clinical Pharmacokinetics;2022-10-20